Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for AbbVie
Company Monitoring Page for AbbVie
latest headlines for company on cafepharma
Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
Marketwatch
Mon, 07/22/19 - 10:15 am
Tags:
Celgene
,
Biogen
,
AbbVie
,
Bristol-Myers Squibb
,
earnings
8 More Big Pharma Events in 2019 You Don't Want to Miss
Motley Fool
Mon, 07/22/19 - 09:44 am
Tags:
Novartis
,
Pfizer
,
AbbVie
,
Bristol-Myers Squibb
,
Merck
,
GSK
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
Yahoo/Zacks.com
Sat, 07/20/19 - 08:19 pm
Tags:
AbbVie
,
earnings
AbbVie jumps into STING cancer work with Mavupharma buy
Fierce Biotech
Mon, 07/15/19 - 10:55 am
Tags:
AbbVie
,
Mavupharma
,
M&A
,
STING
,
immuno-oncology
NICE recommends funding for psoriasis and type 1 diabetes drugs
Pharmaforum
Fri, 07/12/19 - 12:14 pm
Tags:
NICE
,
UK
,
NHS
,
AbbVie
,
Skyrizi
,
AstraZeneca
,
Farxiga
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Fierce Pharma
Thu, 07/11/19 - 09:45 am
Tags:
AbbVie
,
Humira
,
Gilead Sciences
,
Biktarvy
,
Truvada
,
Pfizer
,
Xeljanz
,
television ads
,
DTC ads
Why AbbVie's Stock Sank in the First Half of 2019
Motley Fool
Fri, 07/5/19 - 01:51 pm
Tags:
AbbVie
,
Humira
,
biosimilars
,
M&A
,
Allergan
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Tue, 07/2/19 - 10:46 am
Tags:
Gilead Sciences
,
AbbVie
,
FDA
,
JAK inhibitors
,
filgotinib
,
Upadacitinib
,
rheumatoid arthritis
Are AbbVie and Allergan Really Better Together?
Motley Fool
Fri, 06/28/19 - 12:23 pm
Tags:
AbbVie
,
Allergan
,
M&A
AbbVie deal for Allergan not about the taxes thanks to 2017 law
Biopharma Dive
Thu, 06/27/19 - 09:41 am
Tags:
Allergan
,
AbbVie
,
M&A
,
taxes
5 reasons AbbVie bought Allergan, and why they may not be enough
Biopharma Dive
Wed, 06/26/19 - 04:57 pm
Tags:
AbbVie
,
Allergan
,
M&A
,
Humira
,
Botox
,
cash
,
diversification
Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch
Endpoints
Wed, 06/26/19 - 11:51 am
Tags:
AbbVie
,
Allergan
,
M&A
,
R&D
,
layoffs
Here's Why Nobody's Happy About This $63 Billion Buyout
Motley Fool
Wed, 06/26/19 - 10:41 am
Tags:
AbbVie
,
Allergan
,
M&A
How Brent Saunders’ Allergan experiment failed
Stat
Wed, 06/26/19 - 10:12 am
Tags:
Brent Saunders
,
Allergan
,
AbbVie
,
Pharma CEOs
AbbVie’s $63 Billion Mistake
Motley Fool
Tue, 06/25/19 - 07:20 pm
Tags:
AbbVie
,
Allergan
,
M&A
FDA lifts hold on AbbVie multiple myeloma study
Biopharma Dive
Tue, 06/25/19 - 07:19 pm
Tags:
FDA
,
AbbVie
,
Venclexta
,
clinical trials
,
Multiple Myeloma
AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants
Stat
Tue, 06/25/19 - 09:18 am
Tags:
AbbVie
,
Allergan
,
M&A
,
Humira
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud
Endpoints
Mon, 06/24/19 - 10:54 am
Tags:
AbbVie
,
Venclexta
,
Multiple Myeloma
,
FDA
,
clinical trials
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
Tags:
AbbVie
,
Upadacitinib
,
rheumatoid arthritis
,
Novartis
,
brolucizumab
,
wet age-related macular degeneration
,
Celgene
,
ozanimod
,
relapsing multiple sclerosis
Abbvie proves the best at getting the most out of its workers
EP Vantage
Fri, 06/21/19 - 09:44 am
Tags:
AbbVie
,
Bristol-Myers Squibb
,
Sanofi
,
AstraZeneca
,
revenue per employee
Pages
« first
‹ previous
…
29
30
31
32
33
34
35
36
37
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
An earthquake would most likely shake a: idea, building, breeze
*
Fill in the blank.